Related Experiment Video
Updated: Feb 3, 2026

Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer
1Thomas Powles, Royal Free Hospital, and Queen Mary University of London, London, United Kingdom; and Brian Rini, Lerner College of Medicine, and Cleveland Clinic, Cleveland, OH.
Abstract:
The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to immune checkpoint inhibitors and novel combinations. Specifically, recent data with programmed death ligand inhibitors is revolutionizing the standard approach to metastatic renal cell carcinoma. However, there is speculation around a number of newer potentially therapeutic targets, such as indoleamine 2,3-dioxygenase, transforming growth factor-β, interleukin-10, and adenosine. In this article, we review novel treatments, promising combinations, and consideration in both trial design and clinical application of therapeutics that will influence practice in the future.
Insights
The treatment of metastatic clear cell renal cancer is shifting towards immune checkpoint inhibitors and new combinations. Emerging targets like indoleamine 2,3-dioxygenase show promise for future therapies.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Metastatic clear cell renal cancer treatment is evolving rapidly.
- The paradigm is shifting from vascular endothelial growth factor-targeted therapies to immune checkpoint inhibitors.
- Novel combinations are becoming the standard of care.
Purpose of the Study:
- To review novel treatments for metastatic renal cell carcinoma.
- To discuss promising therapeutic combinations.
- To consider trial design and clinical application of future therapeutics.
Main Methods:
- Review of recent clinical data and emerging research.
- Analysis of immune checkpoint inhibitors and novel targets.
- Discussion of future therapeutic strategies.
Main Results:
- Programmed death ligand inhibitors are revolutionizing treatment approaches.
- New targets such as indoleamine 2,3-dioxygenase, transforming growth factor-β, interleukin-10, and adenosine are under investigation.
- Novel combinations and future therapeutics show significant potential.
Conclusions:
- Immune checkpoint inhibitors represent a major advancement in metastatic renal cell carcinoma treatment.
- Further research into novel targets and combinations is crucial.
- These advancements will significantly influence future clinical practice.
Related Concept Videos
Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Drug Elimination: Non-Renal Routes
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Antidepressant Drugs: MAOIs and Other Agents
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
The pKa of a...

